Menu Search
Equities

Xenon Pharmaceuticals Inc

XENE:NMQ

Xenon Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)43.39
  • Today's Change-0.68 / -1.54%
  • Shares traded473.99k
  • 1 Year change+50.50%
  • Beta1.2034
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Xenon Pharmaceuticals Inc's revenues fell -100.00% from 9.43m to 0.00. has fallen 45.48% from a loss of 125.37m to a larger loss of 182.39m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-25.38%
Return on equity-26.71%
Return on investment-26.37%
More ▼

Cash flow in USDView more

In 2023, Xenon Pharmaceuticals Inc increased its cash reserves by 159.67%, or 91.40m. Cash Flow from Financing totalled 353.52m or -- of revenues. In addition the company used 145.33m for operations while cash used for investing totalled 117.17m.
Cash flow per share-2.68
Price/Cash flow per share--
Book value per share11.15
Tangible book value per share11.15
More ▼

Balance sheet in USDView more

Xenon Pharmaceuticals Inc has a strong Balance Sheet and has consistently grown its cash reserves over the last Four years to total 148.64m.
Current ratio23.27
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.